Let's take the plunge because we don't have a minute to spare.

SmallCapFirm

(CTXR) Is A Former Nasdaq Breakout Champ With Strong Analyst Price Targets (Key Details Now)

Last Week's Profiles Ran Approx. 22% and 25% Short Term...

September 22nd

SCF Readers,

Let's take the plunge because we don't have a minute to spare.

Last week, I brought two separate Nasdaq profiles to your attention and they both delivered.

With the overall Nasdaq market dipping some 800 points from Monday through Friday, my two alerts ran approximately 22% and and 25% in the short term.

Good stuff, but let's keep moving forward.

On April 19th, 2021, I brought this biopharma profile to your attention only to watch it run from an open that day of $1.99 to a high of $4.56 by June 22nd.

Overall, that $2.00+ surge resulted in this breakout idea running approximately 129%.

Now, with several potential catalysts including strong analyst coverage with significant price targets, plus key program updates and multiple oversold leaning technicals, you literally can't wait another second to get this company pulled up.

For Friday, September 23rd, there is only one Nasdaq biopharma idea to have on your watch-list:

*Citius Pharmaceuticals, Inc. (CTXR)*

Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies.

And right now, this profile has 4 potential catalysts to be fully aware of. They include:

No. 1 - Strong Analyst Coverage Including A Pair Of $6.00 Targets

No. 2 - Important Business Update Shows Company's Overly Encouraging Path

No. 3 - Company Aims To Optimize Commercialization Efforts Of 2 Late-Stage Product Candidates

No. 4 - Key Technical Indicators Are Leaning Oversold

But more on those in a second...

Citius Pharmaceuticals, Inc. (CTXR) Could Be A BioPharma Powerhouse Hiding In Plain Sight

Citius Pharmaceuticals is what’s called a “late-stage biopharmaceutical” company, where a highly-experienced management team purchases rights to the most promising new therapies and then either brings them to market or licenses rights to bigger pharma companies like Pfizer or Johnson & Johnson.

It should go without saying that “late-stage” development is the most difficult, most expensive part of the process for any new kind of treatment. Because even after years of investment, research and development, some 2 out of 5 drugs still fail to secure final FDA approval.

But with a “Dream Team” of top industry insiders, Citius is turning the odds in their favor—with two treatments now in Phase 3, and both looking like they will pass.

image

(Source)

In addition to E-7777, it’s currently advancing three proprietary product candidates in total:

  • CITI-002 (Halo-Lido), a topical formulation of halobetasol, a corticosteroid, and lidocaine to provide anti-inflammatory and anesthetic symptomatic relief to hemorrhoids victims. It is currently gearing up for a Phase IIb trial.
  • CITI-101 (Mino-Wrap), a liquefying gel-based wrap containing minocycline and rifampin designed to provide inflammatory tissue protection and prevent infection and biofilm formation in tissue expanders and breast implants post-mastectomy. In December 2020, Citius received a written response and guidance from the USFDA for Mino-Wrap development. Citius expects to file for an IND by the end of this year.
  • Mino-Lok, an antibiotic lock solution developed as adjunctive therapy for patients with central line-associated bloodstream infections (CLABSIs) or catheter-related bloodstream infections (CRBSIs). If approved, Citius believes that Mino-Lok could enter a $1.5Bn worth market and prove to be a blockbuster without any immediate competition.

-----

And right now, CTXR has 4 potential catalysts to soak in this second. Following along...

No. 1 CTXR Potential Catalyst - Strong Analyst Coverage Including A Pair Of $6.00 Targets

Analyst coverage on CTXR is at a premium right now.

Check it out:

image

(Source: MarketBeat)

Each brokerage/analyst has given CTXR a target over 200% higher than this Nasdaq past champ's closing valuation as of Thursday.

What's even better is HC Wainwright has boosted their target from $4.00 to $6.00 in 2022.

Could CTXR really be as undervalued as these brokerages/analysts suppose?

-----

No. 2 CTXR Potential Catalyst - Important Business Update Shows Company's Overly Encouraging Path

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Fi-nan-cial Results and Provides Business Update

$48.0Mn in cash and cash equivalents as of June 30, 2022 to support ongoing programs through August 2023

International sites for Mino-Lok® Phase 3 trial engaged as recruitment accelerates

I/ONTAK Biologics License Application (BLA) on track for 2H 2022 submission

CRANFORD, N.J., Aug. 11, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today reported business and fin-an-cial results for the third fiscal quarter of 2022 ended June 30, 2022.

Fiscal Q3 2022 Business Highlights and Subsequent Developments

  • Mino-Lok® Phase 3 trial recruitment approached pre-CV-19 pace; international trial sites engaged to accelerate trial enrollment; Company reiterates 92 failure events required for trial completion;
  • Halo-Lido Phase 2b trial initiated; enrollment completion anticipated by end of 2022;
  • I/ONTAK (denileukin diftitox) topline results show no new safety signals and are consistent with prior formulation (ONTAK);
  • Pre-BLA meeting held with the FDA for I/ONTAK; biologics license application (BLA) remains on track for submission in the second half of 2022; and,
  • Announced intention to spinoff I/ONTAK into standalone oncology-focused publicly traded company.

...

"Citius made solid progress during the quarter to advance our multiple programs. We expanded the Phase 3 Mino-Lok trial to include international sites with the intention of increasing and accelerating enrollment. Our efforts remain focused on driving patient recruitment, which we believe will hasten trial completion. Based on the current the pace of enrollment and the ramp up of our international sites, we expect to enroll the last patient, to complete the trial by the end of 2022, subsequently with the required number of events," stated Leonard Mazur, Chairman and CEO of Citius.

"Our I/ONTAK program remains on track with an anticipated BLA submission later this year. Topline results for the Phase 3 trial of I/ONTAK were consistent with the prior FDA-approved formulation (ONTAK) and we believe there remains a significant unmet medical need in the market for CTCL patients. We recently completed a pre-BLA meeting with the U.S. Food and Drug Administration (FDA) and appreciate their continued guidance. Additionally, the Halo-Lido Phase 2b trial for the treatment of hemorrhoids was initiated during the quarter and we remain encouraged that we may complete enrollment in this trial by the end of the year," added Mazur.

"Our balance sheet remains strong with $48Mn in cash available and no debt, providing us with greater strategic and financing flexibility than many of our peers. We believe these funds are sufficient to allow us to execute our activities through August 2023..."

...

Read the full article here.

-----

No. 3 CTXR Potential Catalyst - Company Aims To Optimize Commercialization Efforts Of 2 Late-Stage Product Candidates

Citius Pharmaceuticals, Inc. Announces Intention to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company

IPO with distribution of shares to Citius shareholders planned for 2H 2022

Citius would retain Mino-Lok and other pipeline assets and continue to trade on Nasdaq (ticker: CTXR)

CRANFORD, N.J., May 25, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it intends to split the Company's assets into two separate publicly-traded entities. Citius plans to form a new company (NewCo) focused on developing and commercializing I/ONTAK, for which a Phase 3 trial was completed in December 2021 and a biologics license application (BLA) is being planned for submission in the second half of 2022. The Company's other pipeline assets, including Mino-Lok®, would remain at Citius. Citius would continue to trade on the Nasdaq exchange under its current ticker CTXR. The strategic action is intended to optimize organizational resources and in-vest-ment capital to support the successful execution of each development program.

"As Citius prepares for the commercialization of its two late-stage product candidates, I/ONTAK and Mino-Lok, we believe that the market has not adequately valued the potential of our recent I/ONTAK licensing agreement. It is our view that a spinoff and IPO would create two focused standalone public companies that are better positioned to pursue their strategic priorities, in-vest in growth opp's and attract new in-vest-ors. Upon completion of the transactions, NewCo would be a pure-play oncology-focused biopharmaceutical company. Citius would retain i0074s Mino-Lok antibiotic lock solution at the core of its diversified pipeline. The planned transactions underscore our commitment to provide patients with superior therapeutics and reinforce our alignment with the needs of shareholders to deliver long term growth. Our intention is that the spinoff will be non-dilutive and tax-fee to Citius shareholders," stated Leonard Mazur, Chairman and CEO of Citius.

Citius intends the spinoff to be accomplished through an initial public offering (IPO) and pro rata distribution of stock in the NewCo to Citius shareholders. The spinoff and distribution of st-ock is expected to occur in a manner intended to qualify as a tax-free transaction for U.S. shareholders.

The transactions are expected to be completed in the second half of calendar year 2022, subject to the satisfaction of customary conditions, including final approval from the Citius Board of Directors, regulatory approvals and SEC filings.

There can be no assurance regarding the ultimate timing of the proposed transaction or that the transaction will be completed at all.

...

Read the full article here.

-----

No. 4 CTXR Potential Catalyst - Key Technical Indicators Are Leaning Oversold

As of 2:00PM EST Thursday, Barchart was reporting this profile to have several oversold leaning technicals.

These technicals could be signaling a healthy reversal in the near term.

Here's the definition of a "reversal" from Investopedia:

"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."

Now, here are some key technicals (as of 2:00PM EST Thursday) that could signal CTXR to be leaning oversold and on the verge of a potential reversal.

  • 9-Day Relative Strength Index: 38.90%

When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.

  • 14-Day Raw Stochastic: 2.38%
  • 14-Day Williams %R: 97.62%

As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued.

Keep an eye on these technicals closely.

-----

CTXR Recap - 4 Potential Catalysts For This Nasdaq Past Champ

No. 1 - Strong Analyst Coverage Including A Pair Of $6.00 Targets

No. 2 - Important Business Update Shows Company's Overly Encouraging Path

No. 3 - Company Aims To Optimize Commercialization Efforts Of 2 Late-Stage Product Candidates

No. 4 - Key Technical Indicators Are Leaning Oversold

-----

Coverage is officially reinitiated on CTXR. When you have time later, do this:

image

Get CTXR on your radar now.

Sincerely,

Axel Adams

Editor, SCF


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)​

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). Disclosure: Make sure to always do your own research and due diligence on any day and swing trade profile I bring to your attention. I am not a license d finan.cial advise r. All potential percentage gains are based on from the low to the high of day. SmallCapFirm's full disclosure is to be read and fully understood before using SmallCapFirm's website, or joining SmallCapFirm's email or text list. By viewing SmallCapFirm's website and/or reading SmallCapFirm's email or text newsletter you are agreeing to SmallCapFirm's full disclosure which can be read at: smallcapfirm.com/disclosure StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaqwirenews . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews was hired for a period beginning on 7/26/19 and ending on 7/29/19 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a period beginning on 9/3/19 and ending on 9/4/19 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a period beginning on 12/18/19 and ending on 12/19/19 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNesWire LLC and Venado Media LLC, StockWireNews has been hired for a one day period on 2/4/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a one day period on 3/11/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a period beginning on 4/2/20 and ending on 4/3/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty-five thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a one day period on 4/28/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a one day period on 5/13/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a two day period beginning on 6/2/20 and ending on 6/3/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid seventeen thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a two day period beginning on 7/7/20 and ending on 7/8/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a two day period beginning on 8/4/20 and ending on 8/5/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid ten thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a two day period beginning on 9/17/20 and ending on 9/18/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a one day period beginning on 10/6/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid ten thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for an additional one day period beginning on 10/8/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid two thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for an additional one day period beginning on 12/8/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid sixty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 2/16/21 and ending on 2/17/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid seventeen thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 4/29/21 and ending on 4/30/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid ninety-five thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 5/18/21 and ending on 5/19/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid five thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 6/8/21 and ending on 6/9/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 6/16/21 and ending on 6/17/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid ninety-five thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 7/8/21 and ending on 7/9/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid seventeen thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 9/7/21 and ending on 9/8/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. StockNewsWire LLC was paid sixty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 12/6/21 and ending on 12/7/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. StockNewsWire LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a one day period on 5/6/22 to publicly disseminate information about (CTXR) via Website, Email and SMS. StockNewsWire LLC was paid eighty-two thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (CTXR). Pursuant to an agreement between SWN Media LLC and Legends Media LLC, SmallCapFirm (SCF) has been hired for a period beginning on 9/22/22 and ending on 9/23/22 to publicly disseminate information about (CTXR) via Website, Email and SMS. SWN Media LLC was paid ninety thousand USD via bank wire transfer. We own zero shares of (CTXR). To date we have now been compensated a total of seven hundred and twenty thousand five hundred USD via bank wire transfer to disseminate information about (CTXR). This ninety thousand USD in compensation has been or will be applied towards profiles on multiple companies including the following: Pursuant to an agreement between SWN Media LLC and Legends Media LLC, SmallCapFirm (SCF) has been hired for a period beginning on 8/23/22 and ending on 8/25/22 to publicly disseminate information about (BSGM) via Website, Email and SMS. SWN Media LLC was paid ninety thousand USD via bank wire transfer. We own zero shares of (BSGM). To date, we have been compensated a total of two hundred and seventy-one thousand USD via bank wire transfer to disseminate information about (BSGM).